VentureMedGroup key facts
as of Oct 2026- Developer of endovascular medical devices intended to address unmet needs in treating peripheral arterial diseases.
- VentureMedGroup is valued at approximately $60.2M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $72.0M across 4 recorded rounds; the latest was Early Stage VC ($49.2M) in Oct 2025.
- Notable investors include S3 Ventures, Ohio Department of Development, Endeavour Vision, Global Cardiovascular Innovation Center, ProMedica Innovations — 7 tracked in total.
- VentureMedGroup has filed 4 Form Ds with the SEC since 2023, most recently Feb 2025 ($7.0M sold to 1 investors).
- Status: Privately Held (backing).
Valued at $60.2M at its later-stage round, Oct 2025. Nothing has traded since.
- ·Watch VentureMedGroup: the Monday email on marks, rounds and moves
VentureMedGroup funding rounds
4 roundsVentureMedGroup valuation
VentureMedGroup was valued at $60.2 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has VentureMedGroup raised?
VentureMedGroup has raised $72 million across 4 recorded rounds since 2022. The largest was a $7 million debt round in Oct 2024; the most recent was a $49.2 million early-stage round in Oct 2025.
VentureMedGroup has filed 4 Form Ds with the SEC since 2023, most recently in Feb 2025 ($7 million sold to 1 investor).
VentureMedGroup investors
7 investors are on record for VentureMedGroup, including S3 Ventures, Ohio Department of Development, Endeavour Vision and Global Cardiovascular Innovation Center. The early-stage round in Oct 2025 drew 2 investors.
About VentureMedGroup
Developer of endovascular medical devices intended to address unmet needs in treating peripheral arterial diseases. The company's devices safely and predictably modify plaque and stenosis by creating controlled, micro-incisions of any length in complex lesions of varying morphology and providing acute luminal gain, improved vessel compliance and consistent, good clinical revascularization outcomes in peripheral arterial disease (PAD), enabling healthcare providers to make vessel preparation simple, quick and cost-effective.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2012
- Employees
- 23
- Website
- flexvascular.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.